Phare Bio
Phare Bio is a social venture using novel AI and Deep Learning to develop new antibiotics to combat antimicrobial resistance. They collaborate with leading institutions like MIT and the Broad Institute, and have received significant funding including from TED's Audacious Project, ARPA-H, and Google.org. Their mission is to rapidly discover and develop novel antibiotics using AI, addressing the global threat of drug-resistant bacteria.
Industries
Nr. of Employees
small (1-50)
Phare Bio
123 Innovation Drive, Cambridge, MA 02139
Products
Generative AI antibiotics discovery platform
A platform that applies generative deep learning and interpretable ML to design, prioritize and accelerate novel antibiotic candidates.
Generative AI antibiotics discovery platform
A platform that applies generative deep learning and interpretable ML to design, prioritize and accelerate novel antibiotic candidates.
Services
Computational design and prioritization of novel antibacterial molecules using generative models and high-throughput in silico screening.
Experimental hit-to-lead and preclinical services including metabolism, toxicology, pharmacokinetics, and in vivo efficacy profiling to derisk candidates.
Analog design, synthesis strategy and coordination of external contract research organizations for compound production and data exchange.
Strategic facilitation of partnerships with external developers or formation of spin‑out entities to enable clinical development of derisked candidates.
Computational design and prioritization of novel antibacterial molecules using generative models and high-throughput in silico screening.
Experimental hit-to-lead and preclinical services including metabolism, toxicology, pharmacokinetics, and in vivo efficacy profiling to derisk candidates.
Analog design, synthesis strategy and coordination of external contract research organizations for compound production and data exchange.
Strategic facilitation of partnerships with external developers or formation of spin‑out entities to enable clinical development of derisked candidates.
Expertise Areas
- AI-driven antibiotic discovery
- Generative deep learning model development
- High-throughput virtual screening
- Hit-to-lead optimization and ADME/Tox
Key Technologies
- Generative deep learning models
- Deep neural networks for activity prediction
- Explainable / interpretable machine learning
- Large-scale virtual screening
News & Updates
A recent publication in Nature describes a new class of antibiotics discovered using explainable deep learning techniques.
A study published in Nature showcases how deep learning guided the discovery of an antibiotic effective against Acinetobacter baumannii.
A publication in Cell details how deep neural networks can predict antibiotic activity in molecules structurally different from known antibiotics.
A study in Cell demonstrates how explainable machine learning can reveal mechanisms of antibiotics.
Phare Bio was awarded the Newsweek AI Impact Award for its innovative use of AI in antibiotic discovery.
Phare Bio and MIT were recognized in Fast Company's list for their innovative contributions to health and technology.
A recent publication in Nature describes a new class of antibiotics discovered using explainable deep learning techniques.
A study published in Nature showcases how deep learning guided the discovery of an antibiotic effective against Acinetobacter baumannii.
A publication in Cell details how deep neural networks can predict antibiotic activity in molecules structurally different from known antibiotics.
A study in Cell demonstrates how explainable machine learning can reveal mechanisms of antibiotics.
Phare Bio was awarded the Newsweek AI Impact Award for its innovative use of AI in antibiotic discovery.
Phare Bio and MIT were recognized in Fast Company's list for their innovative contributions to health and technology.